Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Biography
Dr. Kathleen Poston is the Edward F. and Irene Thiele Pimley Professor in Neurology and Neurological Sciences at Stanford University. She received her Bachelor's of Science in Bioengineering at the University of Pennsylvania, her Master's Degree in Biomedical Engineering and her MD at Vanderbilt University. She completed her Neurology residency training at UCSF, completed a fellowship in clinical Movement Disorders at Columbia University and post-doctoral research training in Functional Neuroimaging at the Feinstein Institute.
Dr. Poston’s research and clinical emphasis is to understand the motor and non-motor impairments, such as dementia, that develop in patients with alpha-synuclein pathology, such as Parkinson’s disease, dementia with Lewy Bodies, and Multiple System Atrophy. Her lab uses functional and structural imaging biomarkers, along with biological and genetic biomarkers, to understand the underlying pathophysiology associated these symptoms. Dr. Poston is Chief of the Movement Disorders Division and holds an appointment in the Memory Disorders division. She is a founding member of the Stanford Alzheimer’s Disease Research Center and co-Director for the Lewy Body Dementia Association Research Center of Excellence at Stanford University, and Director of the Stanford Parkinson’s Foundation Center of Excellence.
Dr. Poston’s research and clinical emphasis is to understand the motor and non-motor impairments, such as dementia, that develop in patients with alpha-synuclein pathology, such as Parkinson’s disease, dementia with Lewy Bodies, and Multiple System Atrophy. Her lab uses functional and structural imaging biomarkers, along with biological and genetic biomarkers, to understand the underlying pathophysiology associated these symptoms. Dr. Poston is Chief of the Movement Disorders Division and holds an appointment in the Memory Disorders division. She is a founding member of the Stanford Alzheimer’s Disease Research Center and co-Director for the Lewy Body Dementia Association Research Center of Excellence at Stanford University, and Director of the Stanford Parkinson’s Foundation Center of Excellence.
View Full Biography
Professional Summary
Education & Certifications
- Fellowship: Columbia University Medical Center (2008) NY
- Residency: University of California San Francisco (2006) CA
- Internship: University of California San Francisco (2003) CA
- Medical Education: Vanderbilt University School of Medicine (2002) TN
- Board Certification: American Board of Psychiatry and Neurology, Neurology (2007)
- Post-Doc, Feinstein Institute, Functional Neuroimaging (2009)
- BSE, University of Pennsylvania, Bioengineering
- MS, Vanderbilt University, Bioengineering (1998)
Honors & Awards
- J. William Langston Award, Michael J Fox Foundation for Parkinson’s Research (2023)
- Lysia Forno Award for Teaching Excellence, Stanford University (2009-2010)
Administrative Appointments
- Chief, Movement Disorders Division (2021 - Present)
Publications
-
Zydis selegilline in the management of Parkinson's disease
Poston, K. L., & Waters, C. (2007). Zydis selegilline in the management of Parkinson's disease. EXPERT OPINION ON PHARMACOTHERAPY, 8(15), 2615–2624. -
Movement disorder emergencies
Poston, K. L., & Frucht, S. J. (2008). Movement disorder emergencies. Presented at the 16th Symposium on the Treatment of Parkinsons Disease, TOKYO,JAPAN: SPRINGER HEIDELBERG. -
Network biomarkers for the diagnosis and treatment of movement disorders
Poston, K. L., & Eidelberg, D. (2009). Network biomarkers for the diagnosis and treatment of movement disorders. NEUROBIOLOGY OF DISEASE, 35(2), 141–147. -
Action tremor of the legs in essential tremor: Prevalence, clinical correlates, and comparison with age-matched controls
Poston, K. L., Rios, E., & Louis, E. D. (2009). Action tremor of the legs in essential tremor: Prevalence, clinical correlates, and comparison with age-matched controls. PARKINSONISM & RELATED DISORDERS, 15(8), 602–605. -
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis
Tang, C. C., Poston, K. L., Eckert, T., Feigin, A., Frucht, S., Gudesblatt, M., … Eidelberg, D. (2010). Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. LANCET NEUROLOGY, 9(2), 149–158. -
Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) with Myoclonus
Poston, K. L., McGovern, R. A., Goldman, J. S., Caccappolo, E., & Mazzoni, P. (2010). Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) with Myoclonus. MOVEMENT DISORDERS, 25(4), 514–516. -
Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease
Tang, C. C., Poston, K. L., Dhawan, V., & Eidelberg, D. (2010). Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease. JOURNAL OF NEUROSCIENCE, 30(3), 1049–56. -
FDG PET in the Evaluation of Parkinson's Disease.
FDG PET in the Evaluation of Parkinson's Disease. (2010). PET Clinics, 5(1), 55–64. -
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., … Feigin, A. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. LANCET NEUROLOGY, 10(4), 309–19. -
Functional brain networks and abnormal connectivity in the movement disorders
Poston, K. L., & Eidelberg, D. (2012). Functional brain networks and abnormal connectivity in the movement disorders. NEUROIMAGE, 62(4), 2261–70. -
Network correlates of disease severity in multiple system atrophy
Poston, K. L., Tang, C. C., Eckert, T., Dhawan, V., Frucht, S., Vonsattel, J.-P., … Eidelberg, D. (2012). Network correlates of disease severity in multiple system atrophy. NEUROLOGY, 78(16), 1237–44. -
A disease-specific metabolic brain network associated with corticobasal degeneration
Niethammer, M., Tang, C. C., Feigin, A., Allen, P. J., Heinen, L., Hellwig, S., … Eidelberg, D. (2014). A disease-specific metabolic brain network associated with corticobasal degeneration. BRAIN, 137, 3036–46. -
Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson's disease.
Müller-Oehring, E. M., Sullivan, E. V., Pfefferbaum, A., Huang, N. C., Poston, K. L., Bronte-Stewart, H. M., & Schulte, T. (2015). Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson's disease. Brain Imaging and Behavior, 9(3), 619–38. -
Compensatory neural mechanisms in cognitively unimpaired Parkinson disease.
Poston, K. L., YorkWilliams, S., Zhang, K., Cai, W., Everling, D., Tayim, F. M., … Menon, V. (2016). Compensatory neural mechanisms in cognitively unimpaired Parkinson disease. Annals of Neurology, 79(3), 448–63. -
Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.
Leaver, K., & Poston, K. L. (2015). Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review. Neuropsychology Review, 25(4), 411–23. -
The effects of dopamine on digit span in Parkinson's disease.
Warden, C., Hwang, J., Marshall, A., Fenesy, M., & Poston, K. L. (2016). The effects of dopamine on digit span in Parkinson's disease. Journal of Clinical Movement Disorders, 3, 5-? -
What light have resting state fMRI studies shed on cognition and mood in Parkinson's disease?
YorkWilliams, S., & Poston, K. L. (2014). What light have resting state fMRI studies shed on cognition and mood in Parkinson's disease? Journal of Clinical Movement Disorders, 1, 4-? -
Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson's disease
Mueller-Oehring, E. M., Sullivan, E. V., Pfefferbaum, A., Huang, N. C., Poston, K. L., Bronte-Stewart, H. M., & Schulte, T. (2015). Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson's disease. BRAIN IMAGING AND BEHAVIOR, 9(3), 619–38. -
Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease.
Hendershott, T. R., Zhu, D., Llanes, S., & Poston, K. L. (2017). Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease. Parkinsonism & Related Disorders. -
gene therapy trial for Parkinson's disease.
Niethammer, M., Tang, C. C., LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., … Feigin, A. (2017). gene therapy trial for Parkinson's disease. JCI Insight, 2(7). -
Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease.
Cholerton, B., Johnson, C. O., Fish, B., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., … Edwards, K. L. (2018). Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism & Related Disorders. -
Abnormal eye movement behavior during reading in Parkinson's disease
Yu, C. Y., Lee, T., Shariati, A., Santini, V., Poston, K., & Liao, Y. J. (2016). Abnormal eye movement behavior during reading in Parkinson's disease. PARKINSONISM & RELATED DISORDERS, 32, 130–32. -
Slower saccadic reading in Parkinson's disease
Jehangir, N., Yu, C. Y., Song, J., Shariati, M. A., Binder, S., Beyer, J., … Liao, Y. J. (2018). Slower saccadic reading in Parkinson's disease. PLOS ONE, 13(1), e0191005. -
Dopaminergic Modulation of Basal Ganglia Connectivity in Parkinson's Disease
Poston, K. L., Shire, W., Joseph, R., Menon, V., & Greicius, M. (2012). Dopaminergic Modulation of Basal Ganglia Connectivity in Parkinson's Disease. ANNALS OF NEUROLOGY. WILEY-BLACKWELL. -
Distinct alterations in Parkinson's medication-state and disease-state connectivity
Ng, B., Varoquaux, G., Poline, J. B., Thirion, B., Greicius, M. D., & Poston, K. L. (2017). Distinct alterations in Parkinson's medication-state and disease-state connectivity. NEUROIMAGE-CLINICAL, 16, 575–85. -
Further study of the Montreal Cognitive Assessment's domain-specific metrics could allow for international data comparison and collaboration
Hendershott, T. R., & Poston, K. L. (2018). Further study of the Montreal Cognitive Assessment's domain-specific metrics could allow for international data comparison and collaboration. PARKINSONISM & RELATED DISORDERS, 48, 101. -
Effects of Dopaminergic Medication on Working Memory in Patients with Parkinson's Disease with and without Mild Cognitive Impairment
Sherman, E., Zhang, K., Everling, D., Marshall, A., YorkWilliams, S., Menon, V., & Poston, K. (2016). Effects of Dopaminergic Medication on Working Memory in Patients with Parkinson's Disease with and without Mild Cognitive Impairment. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
7T MRI subthalamic nucleus atlas for use with 3T MRI
Milchenko, M., Norris, S. A., Poston, K., Campbell, M. C., Ushe, M., Perlmutter, J. S., & Snyder, A. Z. (2018). 7T MRI subthalamic nucleus atlas for use with 3T MRI. JOURNAL OF MEDICAL IMAGING, 5(1), 015002. -
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
Simuni, T., Siderowf, A., Lasch, S., Coffey, C. S., Caspell-Garcia, C., Jennings, D., … Marek, K. (2018). Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. MOVEMENT DISORDERS, 33(5), 771–82. -
Dopamine-Related Dissociation of Cortical and Subcortical Brain Activations in Cognitively Unimpaired Parkinson's Disease Patients OFF and ON Medications.
Kim, J., Zhang, K., Cai, W., YorkWilliams, S., I Ua Cruadhlaoich, M. A., Llanes, S., … Poston, K. L. (2018). Dopamine-Related Dissociation of Cortical and Subcortical Brain Activations in Cognitively Unimpaired Parkinson's Disease Patients OFF and ON Medications. Neuropsychologia. -
Information processing deficit in older adults with HIV infection: A comparison with Parkinson's disease.
Sundaram, S., Muller-Oehring, E. M., Fama, R., Bronte-Stewart, H. M., Poston, K. L., Goodcase, R., … Schulte, T. (2018). Information processing deficit in older adults with HIV infection: A comparison with Parkinson's disease. Neuropsychology. -
Ultra-Low-Dose 18F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs.
Chen, K. T., Gong, E., de Carvalho Macruz, F. B., Xu, J., Boumis, A., Khalighi, M., … Zaharchuk, G. (2018). Ultra-Low-Dose 18F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs. Radiology, 180940. -
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.
Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell-Garcia, C., … Sherer, T. (2018). The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 5(12), 1460–77. -
Motor function impairment in chronic HIV is similar but less severe to that seen in Parkinson's disease
Bronte-Stewart, H., Prabhakar, V., Martin, T., Trager, M., Velisar, A., Koop, M. M., … Schulte, T. (2018). Motor function impairment in chronic HIV is similar but less severe to that seen in Parkinson's disease. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Somatic items on the Beck Depression Inventory-II do not affect self-reported depression severity in Parkinson's disease
Ramirez, V., Hendershott, T. R., Faridi, N., Zhu, D., Tian, L., & Poston, K. L. (2018). Somatic items on the Beck Depression Inventory-II do not affect self-reported depression severity in Parkinson's disease. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Domain-specific impact of cerebral white matter hyperintensities on Parkinson's disease cognitive functioning
Linortner, P., Hendershott, T., & Poston, K. (2018). Domain-specific impact of cerebral white matter hyperintensities on Parkinson's disease cognitive functioning. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Widespread Cortical Thinning in Parkinson's Disease: Findings from the ENIGMA-Parkinson's Disease Working Group
Gutman, B., Bright, J., Rummel, C., Rocha, C. S., Debove, I., Yasuda, C., … van der Werf, Y. (2018). Widespread Cortical Thinning in Parkinson's Disease: Findings from the ENIGMA-Parkinson's Disease Working Group. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Episodic recognition memory and the hippocampus in Parkinson's disease: A review.
Das, T., Hwang, J. J., & Poston, K. L. (2018). Episodic recognition memory and the hippocampus in Parkinson's disease: A review. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior, 113, 191–209. -
Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
Hendershott, T. R., Zhu, D., Llanes, S., Zabetian, C. P., Quinn, J., Edwards, K. L., … Poston, K. L. (2019). Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 34(2), 285–91. -
An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF ASS42 and an APOE epsilon4 allele.
Shahid, M., Kim, J., Leaver, K., Hendershott, T., Zhu, D., Cholerton, B., … Poston, K. L. (2019). An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF ASS42 and an APOE epsilon4 allele. Neurobiology of Disease. -
Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.
Peterson, B., Armstrong, M., Galasko, D., Galvin, J. E., Goldman, J., Irwin, D., … Boeve, B. (2019). Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research & Therapy, 11(1), 23. -
Accurate differential diagnosis of parkinsonism by pattern analysis of metabolic imaging data
Tang, C., Dhawan, V., Poston, K., Feigin, A., & Eidelberg, D. (2010). Accurate differential diagnosis of parkinsonism by pattern analysis of metabolic imaging data. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Cognitive Performance in Parkinson's Disease in the Brain Health Registry.
Cholerton, B., Weiner, M. W., Nosheny, R. L., Poston, K. L., Scott Mackin, R., Tian, L., … Montine, T. J. (2019). Cognitive Performance in Parkinson's Disease in the Brain Health Registry. Journal of Alzheimer's Disease : JAD. -
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., … Lang, A. E. (2015). Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Annals of Neurology, 78(2), 248–57. -
Hippocampal CA1 subfield predicts episodic memory impairment in Parkinson's disease.
La, C., Linortner, P., Bernstein, J. D., Ua Cruadhlaoich, M. A., Fenesy, M., Deutsch, G. K., … Poston, K. L. (2019). Hippocampal CA1 subfield predicts episodic memory impairment in Parkinson's disease. NeuroImage. Clinical, 23, 101824. -
Cognitive Performance in Parkinson's Disease in the Brain Health Registry
Cholerton, B., Weiner, M. W., Nosheny, R. L., Poston, K. L., Mackin, R. S., Tian, L., … Montine, T. J. (2019). Cognitive Performance in Parkinson's Disease in the Brain Health Registry. JOURNAL OF ALZHEIMERS DISEASE, 68(3), 1029–38. -
Episodic recognition memory and the hippocampus in Parkinson's disease: A review
Das, T., Hwang, J. J., & Poston, K. L. (2019). Episodic recognition memory and the hippocampus in Parkinson's disease: A review. CORTEX, 113, 191–209. -
Ultra-Low-Dose F-18-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs
Chen, K. T., Gong, E., Macruz, F. B. de C., Xu, J., Boumis, A., Khalighi, M., … Zaharchuk, G. (2019). Ultra-Low-Dose F-18-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs. RADIOLOGY, 290(3), 649–56. -
Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.
Sundaram, S., Hughes, R. L., Peterson, E., Muller-Oehring, E. M., Bronte-Stewart, H. M., Poston, K. L., … Schulte, T. (2019). Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease. Neuroscience and Biobehavioral Reviews. -
Self-reported physical activity levels and clinical progression in early Parkinson's disease
Amara, A. W., Chahine, L., Seedorff, N., Caspell-Garcia, C. J., Coffey, C., Simuni, T., … Taucher, J. (2019). Self-reported physical activity levels and clinical progression in early Parkinson's disease. PARKINSONISM & RELATED DISORDERS, 61, 118–25. -
Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings
Peterson, B., Armstrong, M., Galasko, D., Galvin, J. E., Goldman, J., Irwin, D., … Boeve, B. (2019). Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. ALZHEIMERS RESEARCH & THERAPY, 11. -
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort
Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell-Garcia, C., … Sherer, T. (2018). The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 5(12), 1460–77. -
Information Processing Deficit in Older Adults With HIV Infection: A Comparison With Parkinson's Disease
Sundaram, S., Mueller-Oehring, E. M., Fama, R., Bronte-Stewart, H. M., Poston, K. L., Goodcase, R., … Schulte, T. (2019). Information Processing Deficit in Older Adults With HIV Infection: A Comparison With Parkinson's Disease. NEUROPSYCHOLOGY, 33(2), 157–68. -
Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications
Kim, J., Zhang, K., Cai, W., YorkWilliams, S., Cruadhlaoich, M. A. I. U., Llanes, S., … Poston, K. L. (2018). Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications. NEUROPSYCHOLOGIA, 119, 24–33. -
Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease
Cholerton, B., Johnson, C. O., Fish, B., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., … Edwards, K. L. (2018). Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. PARKINSONISM & RELATED DISORDERS, 50, 29–36. -
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
Prakash, N., Caspell-Garcia, C., Coffey, C., Siderowf, A., Tanner, C. M., Kieburtz, K., … Tauscher, J. (2019). Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). PARKINSONISM & RELATED DISORDERS, 62, 201–9. -
Hippocampal CA1 subfield predicts episodic memory impairment in Parkinson's disease
La, C., Linortner, P., Bernstein, J. D., Cruadhlaoich, M. A. I. U., Fenesy, M., Deutsch, G. K., … Poston, K. L. (2019). Hippocampal CA1 subfield predicts episodic memory impairment in Parkinson's disease. NEUROIMAGE-CLINICAL, 23. -
Amyloid Deposition on PET Correlates with CSF Biomarkers and Cognitive Dysfunction in Parkinson's Disease
Kim, J., Linortner, P., Toueg, T., Mormino, E. C., & Poston, K. L. (2019). Amyloid Deposition on PET Correlates with CSF Biomarkers and Cognitive Dysfunction in Parkinson's Disease. ANNALS OF NEUROLOGY. WILEY. -
MRI biomarkers of motor and non-motor symptoms in Parkinson's disease.
Ryman, S. G., & Poston, K. L. (2019). MRI biomarkers of motor and non-motor symptoms in Parkinson's disease. Parkinsonism & Related Disorders. -
Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures
Chahine, L. M., Siderowf, A., Barnes, J., Seedorff, N., Caspell-Garcia, C., Simuni, T., … Tauscher, J. (2019). Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. JOURNAL OF PARKINSONS DISEASE, 9(4), 665–79. -
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni, T., Uribe, L., Cho, H. R., Caspell-Garcia, C., Coffey, C. S., Siderowf, A., … Marek, K. (2019). Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. The Lancet. Neurology. -
Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease.
Morris, R., Martini, D. N., Smulders, K., Kelly, V. E., Zabetian, C. P., Poston, K., … Horak, F. (2019). Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease. Parkinsonism & Related Disorders, 69, 104–10. -
Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease
Cholerton, B., Poston, K. L., Tian, L., Quinn, J. F., Chung, K. A., Hiller, A. L., … Zabetian, C. P. (2020). Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease. MOVEMENT DISORDERS CLINICAL PRACTICE, 7(1), 61–69. -
Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
Wilson, E. N., Swarovski, M. S., Linortner, P., Shahid, M., Zuckerman, A. J., Wang, Q., … Andreasson, K. I. (2020). Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau. Brain : a Journal of Neurology. -
Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni, T., Brumm, M. C., Uribe, L., Caspell-Garcia, C., Coffey, C. S., Siderowf, A., … Marek, K. (2020). Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. Movement Disorders : Official Journal of the Movement Disorder Society. -
Substantia Nigra Volume Dissociates Bradykinesia and Rigidity from Tremor in Parkinson's Disease: A 7 Tesla Imaging Study.
Poston, K. L., Ua Cruadhlaoich, M. A., Santoso, L. F., Bernstein, J. D., Liu, T., Wang, Y., … Zeineh, M. M. (2020). Substantia Nigra Volume Dissociates Bradykinesia and Rigidity from Tremor in Parkinson's Disease: A 7 Tesla Imaging Study. Journal of Parkinson's Disease, 10(2), 591–604. -
Alterations of Brain Signal Oscillations in Older Individuals with HIV Infection and Parkinson's Disease.
Muller-Oehring, E. M., Hong, J.-Y., Hughes, R. L., Kwon, D., Bronte-Stewart, H. M., Poston, K. L., & Schulte, T. (2020). Alterations of Brain Signal Oscillations in Older Individuals with HIV Infection and Parkinson's Disease. Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology. -
White Matter Hyperintensities Related to Parkinson's Disease Executive Function
Linortner, P., McDaniel, C., Shahid, M., Levine, T. F., Tian, L., Cholerton, B., & Poston, K. L. (2020). White Matter Hyperintensities Related to Parkinson's Disease Executive Function. MOVEMENT DISORDERS CLINICAL PRACTICE. -
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study
Simuni, T., Brumm, M. C., Uribe, L., Caspell-Garcia, C., Coffey, C. S., Siderowf, A., … Marek, K. (2020). Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. MOVEMENT DISORDERS, 35(5), 833–44. -
Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases.
Mormino, E. C., Toueg, T. N., Azevedo, C., Castillo, J. B., Guo, W., Nadiadwala, A., … Chin, F. T. (2020). Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging. -
Hallucinations and Development of Dementia in Parkinson's Disease.
Gryc, W., Roberts, K. A., Zabetian, C. P., Weintraub, D., Trojanowski, J. Q., Quinn, J. F., … Cholerton, B. A. (2020). Hallucinations and Development of Dementia in Parkinson's Disease. Journal of Parkinson's Disease. -
White Matter Hyperintensities Related to Parkinson's Disease Executive Function.
Linortner, P., McDaniel, C., Shahid, M., Levine, T. F., Tian, L., Cholerton, B., & Poston, K. L. (2020). White Matter Hyperintensities Related to Parkinson's Disease Executive Function. Movement Disorders Clinical Practice, 7(6), 629–638. -
Modeling PD Progression in the PPMI Cohort: Implications for Clinical Trial Design
Coffey, C., Brumm, M., Siderowf, A., Simuni, T., Galasko, D., Mollenhauer, B., … Daegle, N. (2020). Modeling PD Progression in the PPMI Cohort: Implications for Clinical Trial Design. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
APOE epsilon 4-related differences in visuospatial impairment in female Parkinson's Disease patients
Rawls, A., Yang, L., Chung, K., Hiller, A., Espay, A., Revilla, F., … Cholerton, B. (2020). APOE epsilon 4-related differences in visuospatial impairment in female Parkinson's Disease patients. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PPMI 2.O New Science/New Cohorts - Transforming PPMI
Marek, K., Siderowf, A., Kieburtz, K., Coffey, C., Foroud, T., Chahine, L., … Tanner, C. (2020). PPMI 2.O New Science/New Cohorts - Transforming PPMI. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Multivariate prediction of dementia in Parkinson's disease.
Phongpreecha, T., Cholerton, B., Mata, I. F., Zabetian, C. P., Poston, K. L., Aghaeepour, N., … Montine, T. J. (2020). Multivariate prediction of dementia in Parkinson's disease. NPJ Parkinson's Disease, 6, 20. -
Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease.
Martini, D. N., Morris, R., Kelly, V. E., Hiller, A., Chung, K. A., Hu, S.-C. C., … Horak, F. (2020). Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease. Frontiers in Neurology, 11, 893. -
Cognitive and motor deficits in older adults with HIV infection: Comparison with normal ageing and Parkinson's disease.
Müller-Oehring, E. M., Fama, R., Levine, T. F., Hardcastle, C., Goodcase, R., Martin, T., … Schulte, T. (2020). Cognitive and motor deficits in older adults with HIV infection: Comparison with normal ageing and Parkinson's disease. Journal of Neuropsychology. -
Quantitative Digitography Measures Fine Motor Disturbances in Chronically Treated HIV Similar to Parkinson’s Disease
Prabhakar, V., Martin, T., Müller-Oehring, E. M., Goodcase, R., Schulte, T., Poston, K. L., & Brontë-Stewart, H. M. (2020). Quantitative Digitography Measures Fine Motor Disturbances in Chronically Treated HIV Similar to Parkinson’s Disease. Frontier in Aging Neuroscience, 539598. -
Vision-based Estimation of MDS-UPDRS Gait Scores for Assessing Parkinson's Disease Motor Severity.
Lu, M., Poston, K., Pfefferbaum, A., Sullivan, E. V., Fei-Fei, L., Pohl, K. M., … Adeli, E. (2020). Vision-based Estimation of MDS-UPDRS Gait Scores for Assessing Parkinson's Disease Motor Severity. Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention, 12263, 637–47. -
Single-cell peripheral immunoprofiling of Alzheimer's and Parkinson's diseases.
Phongpreecha, T., Fernandez, R., Mrdjen, D., Culos, A., Gajera, C. R., Wawro, A. M., … Montine, T. J. (2020). Single-cell peripheral immunoprofiling of Alzheimer's and Parkinson's diseases. Science Advances, 6(48). -
Dopamine transporter imaging predicts clinically-defined a-synucleinopathy in REM sleep behavior disorder.
Chahine, L. M., Brumm, M. C., Caspell-Garcia, C., Oertel, W., Mollenhauer, B., Amara, A., … Iranzo, A. (2020). Dopamine transporter imaging predicts clinically-defined a-synucleinopathy in REM sleep behavior disorder. Annals of Clinical and Translational Neurology. -
Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aß.
Zarifkar, P., Kim, J., La, C., Zhang, K., YorkWilliams, S., Levine, T. F., … Poston, K. L. (2021). Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aß. Parkinsonism & Related Disorders, 83, 71–78. -
Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology.
Ryman, S. G., Yutsis, M., Tian, L., Henderson, V. W., Montine, T. J., Salmon, D. P., … Poston, K. L. (2021). Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology. Journal of Alzheimer's Disease : JAD. -
Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism.
Schindlbeck, K. A., Gupta, D. K., Tang, C. C., O'Shea, S. A., Poston, K. L., Choi, Y. Y., … Eidelberg, D. (2021). Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging. -
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
Kremer, T., Taylor, K. I., Siebourg-Polster, J., Gerken, T., Staempfli, A., Czech, C., … Mollenhauer, B. (2021). Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. -
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
Laansma, M. A., Bright, J. K., Al-Bachari, S., Anderson, T. J., Ard, T., Assogna, F., … van der Werf, Y. D. (2021). International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. -
Mnemonic Similarity Task to study episodic memory in Parkinson's disease.
Das, T., Kim, N., McDaniel, C., & Poston, K. L. (2020). Mnemonic Similarity Task to study episodic memory in Parkinson's disease. Clinical Parkinsonism & Related Disorders, 3, 100062. -
The effects of mood and cognition on daily functioning and quality of life in older people living with HIV and people with Parkinson's disease.
Patel, S. S., Muller-Oehring, E. M., DeVaughn, S., Fama, R., Bronte-Stewart, H. M., Poston, K. L., & Schulte, T. (2021). The effects of mood and cognition on daily functioning and quality of life in older people living with HIV and people with Parkinson's disease. Neuropsychology. -
Quantifying Parkinson's disease motor severity under uncertainty using MDS-UPDRS videos.
Lu, M., Zhao, Q., Poston, K. L., Sullivan, E. V., Pfefferbaum, A., Shahid, M., … Adeli, E. (2021). Quantifying Parkinson's disease motor severity under uncertainty using MDS-UPDRS videos. Medical Image Analysis, 73, 102179. -
Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease.
Cholerton, B. A., Poston, K. L., Yang, L., Rosenthal, L. S., Dawson, T. M., Pantelyat, A., … Zabetian, C. P. (2021). Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease. Journal of Clinical and Experimental Neuropsychology, 1–12. -
Multivariate prediction of dementia in Parkinson's disease.
Phongpreecha, T., Cholerton, B., Mata, I. F., Zabetian, C. P., Poston, K. L., Aghaeepour, N., … Montine, T. J. (2020). Multivariate prediction of dementia in Parkinson's disease. NPJ Parkinson's Disease, 6(1), 20. -
Association of Short and Long Sleep Duration With Amyloid-beta Burden and Cognition in Aging.
Winer, J. R., Deters, K. D., Kennedy, G., Jin, M., Goldstein-Piekarski, A., Poston, K. L., & Mormino, E. C. (2021). Association of Short and Long Sleep Duration With Amyloid-beta Burden and Cognition in Aging. JAMA Neurology. -
Influence of Common Reference Regions on Regional Tau Patterns in Cross-Sectional and Longitudinal [18F]-AV-1451 PET Data.
Young, C. B., Landau, S. M., Harrison, T. M., Poston, K. L., & Mormino, E. C. (2021). Influence of Common Reference Regions on Regional Tau Patterns in Cross-Sectional and Longitudinal [18F]-AV-1451 PET Data. NeuroImage, 118553. -
High cerebrospinal amyloid-ß 42 is associated with normal cognition in individuals with brain amyloidosis.
Sturchio, A., Dwivedi, A. K., Young, C. B., Malm, T., Marsili, L., Sharma, J. S., … Espay, A. J. (2021). High cerebrospinal amyloid-ß 42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine, 38, 100988. -
Latent brain state dynamics and cognitive flexibility in older adults.
Lee, B., Cai, W., Young, C. B., Yuan, R., Ryman, S., Kim, J., … Menon, V. (2021). Latent brain state dynamics and cognitive flexibility in older adults. Progress in Neurobiology, 102180. -
CD4+ T cells contribute to neurodegeneration in Lewy body dementia.
Gate, D., Tapp, E., Leventhal, O., Shahid, M., Nonninger, T. J., Yang, A. C., … Wyss-Coray, T. (2021). CD4+ T cells contribute to neurodegeneration in Lewy body dementia. Science (New York, N.Y.), eabf7266. -
Low soluble amyloid-beta 42 is associated with smaller brain volume in Parkinson's disease.
Espay, A. J., Lafontant, D.-E., Poston, K. L., Caspell-Garcia, C., Marsili, L., Cho, H. R., … Sturchio, A. (2021). Low soluble amyloid-beta 42 is associated with smaller brain volume in Parkinson's disease. Parkinsonism & Related Disorders, 92, 15–21. -
Single-synapse analyses of Alzheimer's disease implicate pathologic tau, DJ1, CD47, and ApoE.
Phongpreecha, T., Gajera, C. R., Liu, C. C., Vijayaragavan, K., Chang, A. L., Becker, M., … Montine, T. J. (1800). Single-synapse analyses of Alzheimer's disease implicate pathologic tau, DJ1, CD47, and ApoE. Science Advances, 7(51), eabk0473. -
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.
Scott, G. D., Arnold, M. R., Beach, T. G., Gibbons, C. H., Kanthasamy, A. G., Lebovitz, R. M., … Irwin, D. J. (2021). Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 12, 805135. -
Neuroimaging approaches to cognition in Parkinson's disease.
Montaser-Kouhsari, L., Young, C. B., & Poston, K. L. (2022). Neuroimaging approaches to cognition in Parkinson's disease. Progress in Brain Research, 269(1), 257–286. -
Neurofunctional characteristics of executive control in older people with HIV infection: a comparison with Parkinson's disease.
Müller-Oehring, E. M., Hong, J.-Y. Y., Poston, K. L., Brontë-Stewart, H. M., Sullivan, E. V., McGlynn, L., & Schulte, T. (2022). Neurofunctional characteristics of executive control in older people with HIV infection: a comparison with Parkinson's disease. Brain Imaging and Behavior. -
Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson's disease.
Cai, W., Young, C. B., Yuan, R., Lee, B., Ryman, S., Kim, J., … Menon, V. (2022). Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson's disease. Brain : a Journal of Neurology. -
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
Young, C. B., Winer, J. R., Younes, K., Cody, K. A., Betthauser, T. J., Johnson, S. C., … Mormino, E. C. (2022). Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology. -
Multimodal deep learning for Alzheimer's disease dementia assessment.
Qiu, S., Miller, M. I., Joshi, P. S., Lee, J. C., Xue, C., Ni, Y., … Kolachalama, V. B. (2022). Multimodal deep learning for Alzheimer's disease dementia assessment. Nature Communications, 13(1), 3404. -
Cognition as a mediator for gait and balance impairments in GBA-related Parkinson's disease.
Morris, R., Martini, D. N., Ramsey, K., Kelly, V. E., Smulders, K., Hiller, A., … Horak, F. (2022). Cognition as a mediator for gait and balance impairments in GBA-related Parkinson's disease. NPJ Parkinson's Disease, 8(1), 78. -
Parkinson's Progression Markers Initiative brain autopsy program.
Bukhari, S. A., Nudelman, K. N., Rumbaugh, M., Richeson, P., Fox, E. J., Montine, K. S., … Montine, T. J. (2022). Parkinson's Progression Markers Initiative brain autopsy program. Parkinsonism & Related Disorders, 101, 62–65. -
ISOLATED REM SLEEP BEHAVIOR DISORDER IS ASSOCIATED WITH 24-HOUR RHYTHM DISRUPTION
Winer, J., Lok, R., Cahuas, A., Bueno, F., Poston, K., Mormino, E., … During, E. (2022). ISOLATED REM SLEEP BEHAVIOR DISORDER IS ASSOCIATED WITH 24-HOUR RHYTHM DISRUPTION. SLEEP. OXFORD UNIV PRESS INC. -
GaitForeMer: Self-supervised Pre-training of Transformers via Human Motion Forecasting for Few-Shot Gait Impairment Severity Estimation
Endo, M., Poston, K. L., Sullivan, E. V., Fei-Fei, L., Pohl, K. M., & Adeli, E. (2022). GaitForeMer: Self-supervised Pre-training of Transformers via Human Motion Forecasting for Few-Shot Gait Impairment Severity Estimation. MEDICAL IMAGE COMPUTING AND COMPUTER ASSISTED INTERVENTION, MICCAI 2022, PT VIII. SPRINGER INTERNATIONAL PUBLISHING AG. -
GaitForeMer: Self-Supervised Pre-Training of Transformers via Human Motion Forecasting for Few-Shot Gait Impairment Severity Estimation.
Endo, M., Poston, K. L., Sullivan, E. V., Fei-Fei, L., Pohl, K. M., & Adeli, E. (2022). GaitForeMer: Self-Supervised Pre-Training of Transformers via Human Motion Forecasting for Few-Shot Gait Impairment Severity Estimation. Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention, 13438, 130–139. -
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson, E. N., Young, C. B., Ramos Benitez, J., Swarovski, M. S., Feinstein, I., Vandijck, M., … Andreasson, K. I. (2022). Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease. Alzheimer's Research & Therapy, 14(1), 172. -
APOE effects on regional tau in preclinical Alzheimer's disease.
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., … Mormino, E. C. (2023). APOE effects on regional tau in preclinical Alzheimer's disease. Molecular Neurodegeneration, 18(1), 1. -
Prediction of neuropathologic lesions from clinical data.
Phongpreecha, T., Cholerton, B., Bhukari, S., Chang, A. L., De Francesco, D., Thuraiappah, M., … Montine, T. J. (2023). Prediction of neuropathologic lesions from clinical data. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson's disease progression
Kern, F., Fehlmann, T., Violich, I., Alsop, E., Hutchins, E., Kahraman, M., … Keller, A. (2021). Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson's disease progression. NATURE AGING, 1(3), 309-+. -
Illusory Responses across the Lewy Body Disease Spectrum
Shahid, M., Rawls, A., Ramirez, V., Ryman, S., Santini, V. E., Yang, L., … Poston, K. L. (2023). Illusory Responses across the Lewy Body Disease Spectrum. ANNALS OF NEUROLOGY. -
Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel
Sabbagh, M. N., Taylor, A., Galasko, D., Galvin, J. E., Goldman, J. G., Leverenz, J. B., … Quinn, J. F. (2023). Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel. ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 9(1), e12375. -
Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [11 C]UCB-J and [18 F]FDG PET Study.
Andersen, K. B., Hansen, A. K., Schacht, A. C., Horsager, J., Gottrup, H., Klit, H., … Borghammer, P. (2023). Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [11 C]UCB-J and [18 F]FDG PET Study. Movement Disorders : Official Journal of the Movement Disorder Society. -
Cognitive Impairment in Neurodegenerative Movement Disorders.
Abdelnour, C., & Poston, K. L. (2023). Cognitive Impairment in Neurodegenerative Movement Disorders. Seminars in Neurology. -
Computerized cognitive practice effects in relation to amyloid and tau in preclinical Alzheimer's disease: Results from a multi-site cohort.
Young, C. B., Mormino, E. C., Poston, K. L., Johnson, K. A., Rentz, D. M., Sperling, R. A., & Papp, K. V. (2023). Computerized cognitive practice effects in relation to amyloid and tau in preclinical Alzheimer's disease: Results from a multi-site cohort. Alzheimer's & Dementia (Amsterdam, Netherlands), 15(1), e12414. -
Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022.
Abdelnour, C., Gonzalez, M. C., Gibson, L. L., Poston, K. L., Ballard, C. G., Cummings, J. L., & Aarsland, D. (2023). Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022. Neurology and Therapy. -
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using a-synuclein seed amplification: a cross-sectional study.
Siderowf, A., Concha-Marambio, L., Lafontant, D.-E. E., Farris, C. M., Ma, Y., Urenia, P. A., … Soto, C. (2023). Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using a-synuclein seed amplification: a cross-sectional study. The Lancet. Neurology, 22(5), 407–417. -
Episodic memory deficit in HIV infection: common phenotype with Parkinson's disease, different neural substrates.
Fama, R., Müller-Oehring, E. M., Levine, T. F., Sullivan, E. V., Sassoon, S. A., Asok, P., … Schulte, T. (2023). Episodic memory deficit in HIV infection: common phenotype with Parkinson's disease, different neural substrates. Brain Structure & Function. -
Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson's disease progression.
Kern, F., Fehlmann, T., Violich, I., Alsop, E., Hutchins, E., Kahraman, M., … Keller, A. (2021). Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson's disease progression. Nature Aging, 1(3), 309–322. -
Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.
Ryman, S. G., Shaff, N., Dodd, A., Nitschke, S., Wertz, C., Julio, K., … Mayer, A. (2023). Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. -
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
Weintraub, D., Picillo, M., Cho, H. R., Caspell-Garcia, C., Blauwendraat, C., Brown, E. G., … Tanner, C. M. (2023). Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study. MOVEMENT DISORDERS CLINICAL PRACTICE. -
Gait and balance in apolipoprotein ?4 allele carriers in older adults and Parkinson's disease.
Morris, R., Martini, D. N., Kelly, V. E., Smulders, K., Ramsey, K., Hiller, A., … Horak, F. (2023). Gait and balance in apolipoprotein ?4 allele carriers in older adults and Parkinson's disease. Clinical Parkinsonism & Related Disorders, 9, 100201. -
Metrologically Traceable Quantification of 3 Apolipoprotein E Isoforms in Cerebrospinal Fluid.
Huynh, H.-H., Kuch, K., Orquillas, A., Forrest, K., Barahona-Carrillo, L., Keene, D., … Hoofnagle, A. N. (2023). Metrologically Traceable Quantification of 3 Apolipoprotein E Isoforms in Cerebrospinal Fluid. Clinical Chemistry. -
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study.
Weintraub, D., Picillo, M., Cho, H. R., Caspell-Garcia, C., Blauwendraat, C., Brown, E. G., … Tanner, C. M. (2023). Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study. Movement Disorders Clinical Practice, 10(6), 943–955. -
Assessment of heterogeneity among participants in the Parkinson?s Progression Markers Initiative cohort using a-synuclein seed amplification: a cross-sectional study
Siderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., … Soto, C. (2023). Assessment of heterogeneity among participants in the Parkinson?s Progression Markers Initiative cohort using a-synuclein seed amplification: a cross-sectional study. LANCET NEUROLOGY, 22(5), 407–417. -
Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.
Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., … Coffey, C. S. (2023). Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. Journal of Parkinson's Disease. -
An Explainable Geometric-Weighted Graph Attention Network for Identifying Functional Networks Associated with Gait Impairment.
Nerrise, F., Zhao, Q., Poston, K. L., Pohl, K. M., & Adeli, E. (2023). An Explainable Geometric-Weighted Graph Attention Network for Identifying Functional Networks Associated with Gait Impairment. ArXiv. -
Quantitative estimate of cognitive resilience and its medical and genetic associations.
Phongpreecha, T., Godrich, D., Berson, E., Espinosa, C., Kim, Y., Cholerton, B., … Montine, T. J. (2023). Quantitative estimate of cognitive resilience and its medical and genetic associations. Alzheimer's Research & Therapy, 15(1), 192. -
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
Kerestes, R., Laansma, M. A., Owens-Walton, C., Perry, A., van Heese, E. M., Al-Bachari, S., … Harding, I. H. (2023). Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study. Movement Disorders : Official Journal of the Movement Disorder Society. -
Prediction of Phenoconversion Time in REM Sleep Behavior Disorder (RBD) with Brain Metabolic Network and Dopaminergic Imaging: A Longitudinal Study
Tang, C. C., Schindlbeck, K., Nakano, Y., Niethammer, M., Dhawan, V., Poston, K., & Eidelberg, D. (2023). Prediction of Phenoconversion Time in REM Sleep Behavior Disorder (RBD) with Brain Metabolic Network and Dopaminergic Imaging: A Longitudinal Study. ANNALS OF NEUROLOGY. WILEY. -
ATN<sub>PD</sub> Framework Using Biofluid Markers Predicts Cognitive Decline in Early Parkinson's Disease
Cousins, K. A. Q., Irwin, D. J., Tropea, T. F., Rhodes, E., Phillips, J. S., Chen-Plotkin, A. S., … Shaw, L. M. (2023). ATNPD Framework Using Biofluid Markers Predicts Cognitive Decline in Early Parkinson's Disease. ANNALS OF NEUROLOGY. WILEY. -
An Explainable Geometric-Weighted Graph Attention Network for Identifying Functional Networks Associated with Gait Impairment.
Nerrise, F., Zhao, Q., Poston, K. L., Pohl, K. M., & Adeli, E. (2023). An Explainable Geometric-Weighted Graph Attention Network for Identifying Functional Networks Associated with Gait Impairment. Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention, 14221, 723–733. -
Reliability of remote National Alzheimer's Coordinating Center Uniform Data Set data.
Smith, V., Younes, K., Poston, K. L., Mormino, E. C., & Young, C. B. (2023). Reliability of remote National Alzheimer's Coordinating Center Uniform Data Set data. Alzheimer's & Dementia (Amsterdam, Netherlands), 15(4), e12498. -
Longitudinal hippocampal subfields, CSF biomarkers, and cognition in patients with Parkinson disease.
Erhardt, E., Horner, A., Shaff, N., Wertz, C., Nitschke, S., Vakhtin, A., … Ryman, S. (2023). Longitudinal hippocampal subfields, CSF biomarkers, and cognition in patients with Parkinson disease. Clinical Parkinsonism & Related Disorders, 9, 100199. -
Post-translational modifications linked to preclinical Alzheimer's disease-related pathological and cognitive changes.
Abiose, O., Rutledge, J., Moran-Losada, P., Belloy, M. E., Wilson, E. N., He, Z., … Mormino, E. C. (2023). Post-translational modifications linked to preclinical Alzheimer's disease-related pathological and cognitive changes. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
A biological definition of neuronal a-synuclein disease: towards an integrated staging system for research.
Simuni, T., Chahine, L. M., Poston, K., Brumm, M., Buracchio, T., Campbell, M., … Marek, K. (2024). A biological definition of neuronal a-synuclein disease: towards an integrated staging system for research. The Lancet. Neurology, 23(2), 178–190. -
Evaluation of ATNPDFramework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
Cousins, K. A., Irwin, D. J., Tropea, T. F., Rhodes, E., Phillips, J., Chen-Plotkin, A. S., … Shaw, L. M. (2024). Evaluation of ATNPDFramework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease. Neurology, 102(4), e208033. -
Speech patterns during memory recall relates to early tau burden across adulthood.
Young, C. B., Smith, V., Karjadi, C., Grogan, S.-M. M., Ang, T. F., Insel, P. S., … Mormino, E. C. (2024). Speech patterns during memory recall relates to early tau burden across adulthood. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Impaired 24-h activity patterns are associated with an increased risk of Alzheimer's disease, Parkinson's disease, and cognitive decline.
Winer, J. R., Lok, R., Weed, L., He, Z., Poston, K. L., Mormino, E. C., & Zeitzer, J. M. (2024). Impaired 24-h activity patterns are associated with an increased risk of Alzheimer's disease, Parkinson's disease, and cognitive decline. Alzheimer's Research & Therapy, 16(1), 35. -
Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra.
Plastini, M. J., Abdelnour, C., Young, C. B., Wilson, E. N., Shahid-Besanti, M., Lamoureux, J., … Poston, K. L. (2024). Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. Annals of Clinical and Translational Neurology. -
Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease.
Rutledge, J., Lehallier, B., Zarifkar, P., Losada, P. M., Shahid-Besanti, M., Western, D., … Poston, K. L. (2024). Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease. Acta Neuropathologica, 147(1), 52. -
AI-based differential diagnosis of dementia etiologies on multimodal data.
Xue, C., Kowshik, S. S., Lteif, D., Puducheri, S., Jasodanand, V. H., Zhou, O. T., … Kolachalama, V. B. (2024). AI-based differential diagnosis of dementia etiologies on multimodal data. MedRxiv : the Preprint Server for Health Sciences. -
Mag-Net: Rapid enrichment of membrane-bound particles enables high coverage quantitative analysis of the plasma proteome.
Wu, C. C., Tsantilas, K. A., Park, J., Plubell, D., Sanders, J. A., Naicker, P., … MacCoss, M. J. (2024). Mag-Net: Rapid enrichment of membrane-bound particles enables high coverage quantitative analysis of the plasma proteome. BioRxiv : the Preprint Server for Biology. -
Subthalamic nucleus-language network connectivity predicts dopaminergic modulation of speech function in Parkinson's disease.
Cai, W., Young, C. B., Yuan, R., Lee, B., Ryman, S., Kim, J., … Menon, V. (2024). Subthalamic nucleus-language network connectivity predicts dopaminergic modulation of speech function in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 121(22), e2316149121. -
The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
Young, C. B., Cholerton, B., Smith, A. M., Shahid-Besanti, M., Abdelnour, C., Mormino, E. C., … Poston, K. L. (2024). The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials. Neurology, 103(2), e209609. -
Data Independent Acquisition to Inform the Development of Targeted Proteomics Assays Using a Triple Quadrupole Mass Spectrometer.
Plubell, D. L., Huang, E., Spencer, S. E., Poston, K., Montine, T. J., & MacCoss, M. J. (2024). Data Independent Acquisition to Inform the Development of Targeted Proteomics Assays Using a Triple Quadrupole Mass Spectrometer. BioRxiv : the Preprint Server for Biology. -
Concerns with the new biological research criteria for synucleinopathy - Authors' reply.
Simuni, T., Chahine, L. M., Weintraub, D., Poston, K. M., Kopil, C. M., Dunn, B., & Marek, K. (2024). Concerns with the new biological research criteria for synucleinopathy - Authors' reply. The Lancet. Neurology, 23(7), 663–666. -
Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder.
Eidelberg, D., Tang, C., Nakano, Y., Vo, A., Nguyen, N., Schindlbeck, K., … Dhawan, V. (2024). Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder. Research Square. -
Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.
Abdelnour, C., Young, C. B., Shahid-Besanti, M., Smith, A., Wilson, E. N., Ramos Benitez, J., … Poston, K. L. (2024). Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease. Annals of Neurology. -
Development of highly multiplex targeted proteomics assays in biofluids using the Stellar mass spectrometer.
Plubell, D. L., Remes, P. M., Wu, C. C., Jacob, C. C., Merrihew, G. E., Hsu, C., … MacCoss, M. J. (2024). Development of highly multiplex targeted proteomics assays in biofluids using the Stellar mass spectrometer. BioRxiv : the Preprint Server for Biology. -
Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation.
Johns, E., Vossler, H. A., Young, C. B., Carlson, M. L., Winer, J. R., Younes, K., … Mormino, E. C. (2024). Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
AI-based differential diagnosis of dementia etiologies on multimodal data.
Xue, C., Kowshik, S. S., Lteif, D., Puducheri, S., Jasodanand, V. H., Zhou, O. T., … Kolachalama, V. B. (2024). AI-based differential diagnosis of dementia etiologies on multimodal data. Nature Medicine. -
Single-cell peripheral immunoprofiling of lewy body and Parkinson's disease in a multi-site cohort.
Phongpreecha, T., Mathi, K., Cholerton, B., Fox, E. J., Sigal, N., Espinosa, C., … Montine, T. J. (2024). Single-cell peripheral immunoprofiling of lewy body and Parkinson's disease in a multi-site cohort. Molecular Neurodegeneration, 19(1), 59. -
A worldwide study of white matter microstructural alterations in people living with Parkinson's disease.
Owens-Walton, C., Nir, T. M., Al-Bachari, S., Ambrogi, S., Anderson, T. J., Aventurato, Í. K., … van der Werf, Y. (2024). A worldwide study of white matter microstructural alterations in people living with Parkinson's disease. NPJ Parkinson's Disease, 10(1), 151. -
LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Alpha-Synuclein Aggregates.
Chahine, L. M., Lafontant, D.-E. E., Ho Choi, S., Iwaki, H., Blauwendraat, C., Singleton, A. B., … Simuni, T. (2024). LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Alpha-Synuclein Aggregates. MedRxiv : the Preprint Server for Health Sciences. -
Data-driven discovery of movement-linked heterogeneity in neurodegenerative diseases
Endo, M., Nerrise, F., Zhao, Q., Sullivan, E. V., Fei-Fei, L., Henderson, V. W., … Adeli, E. (2024). Data-driven discovery of movement-linked heterogeneity in neurodegenerative diseases. NATURE MACHINE INTELLIGENCE. -
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.
Dam, T., Pagano, G., Brumm, M. C., Gochanour, C., Poston, K. L., Weintraub, D., … Marek, K. (2024). Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts. NPJ Parkinson's Disease, 10(1), 178. -
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.
Dam, T., Pagano, G., Brumm, M. C., Gochanour, C., Poston, K. L., Weintraub, D., … Marek, K. (2024). Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts. MedRxiv : the Preprint Server for Health Sciences.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Adminstration of CERE-120 in Subjects With Idiopathic Parkinson’s Disease
- PaGer Study: Using Multiplex Families to Map Genes That Modify Susceptibility and Age at Onset of Parkinson’s Disease
- Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Practice Locations
Stanford Neuroscience Health Center Palo Alto, CA
Palo Alto, CA
Stanford Neuroscience Health Center
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereMovement Disorders Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Movement Disorders Program in Palo Alto
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(102 reviews)
Sheis very kind and knowledgeable.
Dr. Poston's experience comes through in not only her treatments but her thoughtful and detailed communication plus delightful demeanor.
Dr. Poston takes her time, is responsive and fully engaged with her patients,
Thank you for your thorough assessment of Padma's condition.
She was very nice to talk to but
Dr Poston is wonderful and experienced.
Friendly, through, on time, very efficient
Listens and has good suggestions.
I have recommended Dr.Poston to others.
Dr Poston is kind, caring and knowledgeable.
Dr Poston is a caring and comfortable doctor. She always listens to my concerns
Dr. Poston is excellent. She can be my neurologist forever!
Kathleen Poston is an excellent Dr. She is knowledgeable and caring and she listens well. She thinks about how different symptoms may or may not relate to my Parkinson's. I would highly recommend her.
Dr. Poston is wonderful and knowledgeable,
Dr. Poston was informed, helpful, friendly, and efficient.
Great doctor. Very happy to have her on my team!
Excellent doctor
She is a wonderful, knowledgeable, caring doctor. A credit to her profession.
Dr Poston is an excellent Dr.
Dr. Poston is very professional, pleasant, and communicative. We are continually impressed with her.
She’s great. She always makes sure all of my concerns are addressed by asking if I have any questions and summarizes her impressions to me. Her manner is welcoming and she seems genuinely glad to see me.
The medical care and attention I received was excellent, thoughtful, personally attentive, and timely.
Dr Poston always listens and is honest in what is available.
She took the time to cover a very large range of topics!
Kathleen is so knowledgeable about treatment, current research and implications for diagnosis and treatment. She is friendly and efficient!
Dr. Chatree and Dr. Poston are great. They took lots of time with me and answered all our questions.
Dr Poston is very intensive. See listens to my needs and explains why things are happening.
Very personable answered my questions very professional and would highly recommend her to others
I would definitely recommend Dr. Poston to others.
Dr. Poston was friendly and answered all my questions and concerns thoughtfully and courteously.
I wish you could clone Dr. Poston.
Dr. Poston is an excellent provider. 6. I have done this.
Dr. Poston diagnosed my problem years ago after numerous other specialist had failed to do so & had consistently discussed treatment options at our annual visits while honoring my decision to stick with conservative approach.
So happy with the time and care taken to reply to my many questions.
Dr. Poston is the best! Always feel comfortable and look forward to my annual visit.
Cannot say enough good things about Dr. Poston. She is a wonderful doctor.
I have recommended Dr. Poston to friends. She is the best!
A wonderful physician.
Dr. Poston is the best of the best! We are so pleased to be working with her as we care for our son.
Dr. Poston is the only reason we drove 2-3 hrs. to see her.
I have recommended Dr. Poston to others.
Dr. Poston and her staff are the absolute best! Always answers all of my questions w/detail and possible options. Very easy to communicate with. I always look forward to my annual visit!
Dr. Poston is the best of the best!
I HAVE recommended this doctor to others.
Dr. Poston is extremely caring, thorough, and informative.
Don't want to go to anyone else. Dr. Poston's wonderful.
Dr. Poston has always been excellent. Goes way out of her way to follow up. Really cares.
A good experience!!
Dr. Poston is knowledgeable, courteous, & had a great sensitivity & genuine concern for my issues.
#10. I have recommended Dr. Poston to others.
Very good experience. Dr. Poston and her staff are the best!
Dr. Posten treats Steve like he is her only pt. I especially appreciate her compassion this appt. when she explained his cognative decline gently and in a way that he understands.
Dr. Poston is an excellent care giver & a wonderful person.
Dr. Poston - Great communicator.
Dr. Poston is great - Very knowledgeable, personable, & professional who obviously cares for her patients. I observed her providing coaching to a physician under her supervision - well done, respectful.
Dr. Poston might be the very best doctor our son has ever had at Stanford! We have nothing but great things to say about her and her team.
Entire staff was friendly, open, courteous, and caring.
Could not ask for better care.
Dr. Poston is one of the very best drs. we've ever had for our son!
Dr. Poston is always personable, pleasant, & very knowledgeable. GREAT patient teaching.
This doctor is outstanding! This doctor is consistent. She is ALWAYS interested. I have recommended her to others and she is currently seeing him.
Dr. Poston is a very communicative & caring. Any questions we have are very thoughtful & informative - we are lucky to have her as our physician.
Always very good.
I truly appreciate the care Dr. Poston is providing my husband.
Dr. Poston and her residents are always very pleasant and takes extra time to make sure my husband and I understand my concerns, and care plan.
Honesty, the best physician my husband and I have ever had.
Seemed to remember prior appointment even though a year apart.
Dr. Posten does not talk down to patients. She looks them in the eye and uses words patients can understand.
Dr. Poston has always been excellent. One can tell she really cares about her patients.
My husband has been seeing Dr Kathleen Posten since 2009. She is great.
Very good.
LOVE Dr. Poston! She is unhurried (although I know she's very busy), attentive, & always answers any questions fully, offering solid information.
Dr. Poston is beyond excellent in his knowledge, care, concern, and empathy. I feel lucky to have hes as my husband's neurologist (considering the difficulties in dealing with PD & LBD.
Dr. Poston is wonderful. She is very caring, communicates clearly & listens well. I'm lucky to have her.
Dr. Poston is excellent.
Consistent excellent care.
Dr. Poston is a very knowledgeable doctor. We love her, she's very professional, kind and very understanding. She uses language we can easily understand.
Dr. Posten is awesome
Dr. Poston is excellent!
Dr. Postor took her time to access my condition. She is very courteous and easy to talk to.
Dr. Poston & staff are a pleasure to see.
Dr. Poston's time approach, & ability to communicate are much appreciated - an excellent provider.
my mom tends to get sad over her condition, but dr posten's attitude is so positive and my mom really adopts it---HUGE DEAL! we try to tell my mom to look at the bright side, eh she listens--but when the doctor encourages, she takes it like medicine!
No test or examination has been ordered to reaffirm the diagnosis.
We love Dr. Poston. She always listens carefully, provides good information, helpful, kind, caring. Would have liked more info on potential side effects of increasing med because we had a problem w/this.
Dr. Poston is the best doctor I have ever had. I am 78 years old and have seen many doctors. She is the best!!
Dr. Poston & Kara Richardson were lovely, brilliant, gracious and a dynamic team. We feel blessed to have worked with them.
Dr. Poston ranks as one of the best physicians I've seen in terms of knowledge, experience, health teaching... & accessibility. I'm so pleased to be in her care. Thanks!
Provider is specialist in rare illness.
N/A trial work.
The best!
Experience in all and the best thank you so very much God bless - will recommend.
We are very pleased with Dr. Poston. She has been superior in every way.
Dr. Poston is great! She listens, educates, & makes time for my questions & concerns. She's also clearly enthusiastic & current in her knowledge. MUCH appreciated.
Provider is great in my specific health care problem and instills confidence in her coverage.
Unqualified recommendation!!
Excellent, I'm always impressed by Dr. Poston's manner & teaching. I ALWAYS learn something.
Dr. Poston gave me my life back.
I go home with a positive feeling & filled with hope. Great.
We drive 500 miles round trip to see Dr. Poston.
Highly recommend! Dr. Poston gets an A +.
Dr. Poston and her complete staff are the best!
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records